Medicamen Organics Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Medicamen Organics Ltd is ₹ 29 as of 30 Apr 15:30 . The P/E Ratio of Medicamen Organics Ltd is 0 as of March 2024 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2024 . The Market Cap of Medicamen Organics Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2024 . The Revenue of Medicamen Organics Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Medicamen Organics Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Medicamen Organics Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Medicamen Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Medicamen Organics Ltd

Medicamen Organics Limited was formerly incorporated on March 15, 1995 as Panchdeep Pharmaceuticals Limited', as Public Limited Company dated March 15, 1995 issued by the Registrar of Companies, Delhi and Haryana.
Subsequently, the name of Company changed to Medicamen Organics Limited' and a fresh Certificate of Incorporation on November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. Medicamen Organics are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry Powders for Government (including both State and Central Governments) and Private Institutions as contract manufacturer / third party manufacturer.
The Company market product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Medicamen Organics Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Medicamen Organics Ltd or Vaishali Pharma Ltd?

Market cap of Medicamen Organics Ltd is 33 Cr while Market cap of Vaishali Pharma Ltd is 99 Cr

What are the key factors driving the stock performance of Medicamen Organics Ltd and Vaishali Pharma Ltd?

The stock performance of Medicamen Organics Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Organics Ltd and Vaishali Pharma Ltd?

As of May 4, 2026, the Medicamen Organics Ltd stock price is INR ₹29.0. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.61.

How do dividend payouts of Medicamen Organics Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Medicamen Organics Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.